Letter 10 October: FDA warns patients and health care providers about potential risks associated with compounded ketamine products, including oral formulations, for the treatment of psychiatric disorders

This is what the FDA has just sent out October 10, 2023 What Patients and Health Care Providers Should Know There is increased interest in compounded ketamine products (including oral formulations) for the treatment of psychiatric disorders. When considering use of compounded ketamine products, patients and health care providers should know: Ketamine is not FDA approved for […]

Go to Source

Powered by WPeMatico